9th International Conference on Drug-Drug Interactions (DDI-2006)

Venue: The Edgewater Hotel

Location: Seattle, Washington, United States

Event Date/Time: Jun 20, 2006 End Date/Time: Jun 21, 2006
Registration Date: Jun 20, 2006
Early Registration Date: Apr 03, 2006
Report as Spam


KEY NOTE PRESENTATION: New Horizons in Drug Interactions: Science vs. Clinic (Rene H. Levy, University of Washington; Seattle, WA)

Session I: Current Clinical and Regulatory Status of Drug-Drug Interactions
(Chair: Rene H. Levy)

Salient Features of the 2005-2006 Literature on Drug Interactions (Isabelle Ragueneau-Majlessi, University of Washington; Seattle, WA

Revised FDA Guidance for Drug-Drug Interaction Studies (Soraya Madani, Novartis Pharmaceutical Corp.; Rockville, MD)

FDA Clinical Pharmacology Update (Carol Collins, University of Washington; Seattle, WA)

Session II: Transporter Based Drug-drug Interactions
(Chair: Jashvant D. Unadkat)

Transporter-Related Drug-Drug Interactions in Drug Development (Jiunn H. Lin, Merck & Co., Inc., West Point, PA)

Introduction to Drug Transporters Associated with Drug-Drug Interactions in Kidney and Liver (Raymond Evers, Merck & Co, Rahway, NJ)

Importance of the Integration of Drug Transport and Metabolism for the Prediction of Drug – Drug Interactions (Kenneth R. Brouwer, and John Ansede, Qualyst, Inc., Research Triangle Park, NC)

Drug Interactions at the Blood Brain Barrier: Extrapolating from Rodents to Humans (Jashvant D. Unadkat, University of Washington, Seattle, WA)

Prediction of Transporter-mediated Drug-Drug Interaction from the In Vitro Data (Yoshihisa Shitara(1), Toshiharu Horie(1) and Yuichi Sugiyama(2);(1) Chiba University (2) The University of Tokyo; Tokyo, JAPAN)
Wednesday, June 21, 2006:

Session II: Transporter Based Drug-drug Interactions (continued)

Hepatobiliary Transporters in Drug-Drug Interactions and Toxicities: Case Studies from Millennium Pharmaceutics (Cindy Xia
Millennium Pharmaceuticals, Inc.; Cambridge, MA)

Drug-Drug Interactions of HMG-CoA Reductase Inhibitors (Taro Tokui, Sankyo Co., LTD.; Tokyo, JAPAN)

Session III: In Vitro-In Vivo Correlations
Chair: Magang Shou, Merck, West Point, PA

In Vitro DDI Assays: 1995-2006 (Albert P. Li, The ADMET Group, Rockville, MD)

Microsomal and Hepatocellular Scaling Factors for Use in the Prediction of Human In Vivo Metabolic Clearance (Zoe E. Barter, The University of Sheffield and Simcyp Ltd; Sheffield UK

Quantitative Correlation of In Vitro and In Vivo DDI Resulting from P450 Cooperativity (Wei Tang, Merck & Co., Rahway, NJ)

In Vitro-In Vivo Correlation of Mechanism-based P450 Inhibition (Raimund M. Peter, AstraZeneca, Alderley Park; Macclesfield, UK)

In Vitro: In Vivo Correlation of P450 Inhibition and Induction (Kent Kunze, University of Washington, Seattle, Washington)


2411 Alaskan Way, Pier 67
United States

Additional Information

Early Registration Discounts ans Multiple Event Discounts Available. http://www.isciencex.com/register.htm